IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial
Authors
Keywords
-
Journal
LANCET
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-05-18
DOI
10.1016/s0140-6736(21)00520-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Colchicine in Patients with Chronic Coronary Disease
- (2020) Stefan M. Nidorf et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anticytokine Agents
- (2019) Paul M Ridker CIRCULATION RESEARCH
- Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis
- (2019) Paul M Ridker et al. EUROPEAN HEART JOURNAL
- Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
- (2019) Jean-Claude Tardif et al. NEW ENGLAND JOURNAL OF MEDICINE
- OUP accepted manuscript
- (2018) EUROPEAN HEART JOURNAL
- All roads lead to IL-6: A central hub of cardiometabolic signaling
- (2018) Peter Libby et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease
- (2018) Paul M Ridker et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
- (2018) Paul M Ridker et al. LANCET
- Association of Interleukin 6 Receptor Variant With Cardiovascular Disease Effects of Interleukin 6 Receptor Blocking Therapy
- (2018) Tianxi Cai et al. JAMA Cardiology
- Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
- (2018) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inflammatory Biomarkers Interleukin‐6 and C‐Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial
- (2017) Claes Held et al. Journal of the American Heart Association
- Interleukin‐6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID‐TIMI 52 (Stabilization of Plaque Using Darapladib—Thrombolysis in Myocardial Infarction 52) Trial
- (2017) Christina L. Fanola et al. Journal of the American Heart Association
- From C-Reactive Protein to Interleukin-6 to Interleukin-1
- (2016) Paul M Ridker CIRCULATION RESEARCH
- Inflammation and Progression of CKD: The CRIC Study
- (2016) R. L. Amdur et al. Clinical Journal of the American Society of Nephrology
- Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial
- (2016) Ola Kleveland et al. EUROPEAN HEART JOURNAL
- IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans
- (2015) Nike Müller et al. JOURNAL OF LIPID RESEARCH
- Association of IL-6 and a Functional Polymorphism in the IL-6 Gene with Cardiovascular Events in Patients with CKD
- (2014) B. Spoto et al. Clinical Journal of the American Society of Nephrology
- Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis
- (2013) S. Kaptoge et al. EUROPEAN HEART JOURNAL
- Association between Albuminuria, Kidney Function, and Inflammatory Biomarker Profile in CKD in CRIC
- (2012) J. Gupta et al. Clinical Journal of the American Society of Nephrology
- Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies
- (2012) LANCET
- The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis
- (2012) LANCET
- Inflammation, kidney function and albuminuria in the Framingham Offspring cohort
- (2010) Ashish Upadhyay et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Association of LDL Cholesterol and Inflammation With Cardiovascular Events and Mortality in Hemodialysis Patients With Type 2 Diabetes Mellitus
- (2009) Vera Krane et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease
- (2009) Daniela V. Barreto et al. KIDNEY INTERNATIONAL
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started